secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2026-02-06T23:59:59+00:00
Accession:  0001193125-26-041191
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq notifies Lyra Therapeutics of delisting; company deemed a public shell
-----------------------------------------------------------------------------

- Nasdaq cites public shell status after suspension of lead drug LYR-210 and near-complete workforce reduction.
- Nasdaq also cites non-compliance with minimum $2.5M equity listing rule.
- Company has requested hearing to appeal delisting; stay in effect pending panel decision.
- CEO and CFO now consultants; no ongoing operations after workforce reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000119312526041191/0001193125-26-041191-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000119312526041191/d157841d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-041191

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer